Literature DB >> 28633725

Well-Differentiated Neuroendocrine Tumor-A Low b-Grade Tumor's Aggressive Course and Dismal Outcome: A Case Report.

Dinesh Atwal1, Krishna Prasad Joshi2, Susanne Jeffus3, James Ntambi4, Fade Mahmoud5.   

Abstract

INTRODUCTION: Incidence of well-differentiated neuroendocrine tumors (NETs) of the colon and rectum is increasing and is now approximately 1 per 100,000 in the US. NETs are either well-differentiated (indolent) or poorly differentiated (aggressive). The majority of these tumors are found incidentally during screening colonoscopies and rarely are associated with symptoms of hormonal syndrome, even during the advanced stage. Metastatic well-differentiated NETs of the colon and rectum are incurable, hard to treat, and associated with a poor prognosis and survival rates similar to colorectal adenocarcinoma survival. CASE
PRESENTATION: A 56-year-old man presented to our clinic with right-sided weakness and a 40-pound weight loss during the previous 2 months. A neurologic examination was remarkable for atrophy of the right trapezius muscle and decreased strength in the right upper extremity. Imaging revealed extensive blastic and lytic lesions involving the axial skeleton, a large rectal mass, a large necrotic nodal mass extending from the left iliac region to the level of the left renal veins, and multiple necrotic liver metastasis. Liver lesion fine-needle aspiration findings were consistent with metastatic well-differentiated neuroendocrine carcinoma. DISCUSSION: This case illustrates how a low-grade tumor can have an aggressive course with poor outcomes. Metastatic well-differentiated NETs of the colon and rectum remain difficult to treat because evidence is scarce. More research is needed on this topic.

Entities:  

Mesh:

Year:  2017        PMID: 28633725      PMCID: PMC5478591          DOI: 10.7812/TPP/16-193

Source DB:  PubMed          Journal:  Perm J        ISSN: 1552-5767


  6 in total

1.  Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma.

Authors:  John K Ramage; Peter E Goretzki; Riccardo Manfredi; Paul Komminoth; Diego Ferone; Rudolf Hyrdel; Gregory Kaltsas; Fahrettin Kelestimur; Larry Kvols; Jean-Yves Scoazec; M I Sevilla Garcia; Martyn E Caplin
Journal:  Neuroendocrinology       Date:  2007-11-21       Impact factor: 4.914

Review 2.  Rectal carcinoids.

Authors:  Andrew Y Wang; Nuzhat A Ahmad
Journal:  Curr Opin Gastroenterol       Date:  2006-09       Impact factor: 3.287

3.  Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

Authors:  R Arnold; M E Trautmann; W Creutzfeldt; R Benning; M Benning; C Neuhaus; R Jürgensen; K Stein; H Schäfer; C Bruns; H J Dennler
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

4.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

5.  A 5-decade analysis of 13,715 carcinoid tumors.

Authors:  Irvin M Modlin; Kevin D Lye; Mark Kidd
Journal:  Cancer       Date:  2003-02-15       Impact factor: 6.860

6.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Authors:  James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.